GlassScriptPhysician profile
Vicki L Carr
NPI 1619172202
$21,888.12
in general payments reported to CMS, 2019-2025
41 companies · $5,083 in 2025
The $5,083 reported for 2025 was more than what 83% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,854 · 2020: $483 · 2021: $574 · 2022: $2,019 · 2023: $3,589 · 2024: $6,286 · 2025: $5,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,946 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,661.99 |
| Consulting Fee | $1,946.00 |
| Education | $350.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,938.59 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Genzyme Corporation | $2,630.18 | 2019-2025 | |
| Janssen Biotech, INC. | $1,977.70 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $1,915.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,473.74 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,210.11 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $1,035.50 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Novartis Pharmaceuticals Corporation | $989.96 | 2019-2025 | |
| Amgen INC. | $989.59 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $932.25 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $592.24 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Biofrontera INC. | $507.28 | 2019 | |
| Leo Pharma INC. | $487.14 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $464.52 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Almirall LLC | $458.13 | 2019-2025 | Klisyri, Seysara |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.